A Clinical Trial of Nemtabrutinib in Participants With Severe Kidney Disease (MK-1026-027)

Part of paid clinical trials in Miami Lakes, Florida.

Sponsor
Merck Sharp & Dohme LLC
Study ID
NCT07734610
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Healthy
  • Severe Renal Impairment

Eligibility Criteria

Sex
ALL
Age
18 Years - 80 Years
Healthy Volunteers
Accepted

Interventions

Study Details

The purpose of this study is to learn what happens to nemtabrutinib in a person's body when given to participants with severe kidney disease and to healthy participants.

Key Dates

First listed
Jul 29, 2026
Start date
Sep 17, 2026
Status verified
Sep 2026
Primary completion
Feb 1, 2027
Completion
Feb 1, 2027

Study Design

Enrollment
20 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Nemtabrutinib
    All participants will receive a single oral dose of nemtabrutinib on Day 1.

Primary Outcome Measure

Area Under the Concentration Time Curve From Time 0 Extrapolated to Infinity (AUC0-inf) of Nemtabrutinib in Plasma [ Time Frame: At designated timepoints up to approximately 336 hours postdose ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Floridian Clinical Research, LLC ( Site 0001)Miami LakesFlorida33016
Study Coordinator
305-330-9977

Find similar trials in Miami Lakes, FL

By research site
Floridian Clinical Research, LLC· Miami Lakes, FL

Related Studies